Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study
暂无分享,去创建一个
Xiao-mei Zhang | B. Shen | Yan Zhang | Huayun Zhu | Jianwei Lu | Ning Sun | Jiali Zhu | DeLiang Yang | Geyu Liang
[1] Publisher's Note , 2018, Anaesthesia.
[2] L. Nazer,et al. Comparing the Incidence of Febrile Neutropenia Resulting in Hospital Admission Between the Branded Docetaxel and the Generic Formulations , 2017, Journal of clinical pharmacology.
[3] J. Armitage,et al. Generic oncology drugs: are they all safe? , 2016, The Lancet. Oncology.
[4] M. Smid,et al. Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics , 2015, The Pharmacogenomics Journal.
[5] P. Neven,et al. Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors , 2014, BMC Cancer.
[6] N. Goto,et al. Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials , 2013, International Journal of Clinical Oncology.
[7] E. Chu,et al. Body-surface area-based chemotherapy dosing: appropriate in the 21st century? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Jae Bok Lee,et al. Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. , 2011, Journal of cancer research and therapeutics.
[9] J. Verweij,et al. Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study , 2011, Clinical Cancer Research.
[10] Hitoshi Sato,et al. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia. , 2009, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan.
[11] P. Hérait,et al. Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] G. Hortobagyi,et al. Docetaxel for treatment of solid tumours: a systematic review of clinical data. , 2005, The Lancet. Oncology.
[13] J. Verweij,et al. Relationship of Systemic Exposure to Unbound Docetaxel and Neutropenia , 2005, Clinical pharmacology and therapeutics.
[14] H. Ohmatsu,et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Wolff,et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. , 2004, European journal of cancer.
[16] Roy S Herbst,et al. Mode of action of docetaxel - a basis for combination with novel anticancer agents. , 2003, Cancer treatment reviews.
[17] René Bruno,et al. Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel , 2001, Investigational New Drugs.
[18] K. Korzekwa,et al. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. , 1998, Pharmacogenetics.